Leap Therapeutics, Inc.

NasdaqCM LPTX

Leap Therapeutics, Inc. Free Cash Flow Yield on January 14, 2025: -46.59%

Leap Therapeutics, Inc. Free Cash Flow Yield is -46.59% on January 14, 2025, a 7.18% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Leap Therapeutics, Inc. 52-week high Free Cash Flow Yield is -32.90% on October 29, 2024, which is 29.40% above the current Free Cash Flow Yield.
Leap Therapeutics, Inc. 52-week low Free Cash Flow Yield is -81.42% on July 02, 2024, which is -74.75% below the current Free Cash Flow Yield.
Leap Therapeutics, Inc. average Free Cash Flow Yield for the last 52 weeks is -54.60%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: LPTX

Leap Therapeutics, Inc.

CEO	Mr. Douglas E. Onsi J.D.
IPO Date	Jan. 25, 2017
Location	United States
Headquarters	47 Thorndike Street
Employees	54
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Key trends

Past 5 years